A Novartis drug lowered a risk marker for cardiovascular disease but did not lower chance of heart attack or stroke.

These results, the fact that they're negative, does not invalidate that inflammation plays a very important role in ...

The model is a test of Trump's most-favored nation approach to drug pricing, though its impact is likely to be limited.

Small changes are important, Cohen said about the trial, whose mission was to measure blood pressure reduction, not ...

Katherine MacPhail is a reporter and editorial events programmer for STAT. CHICAGO — What if the key to getting cancer immunotherapy to parts of the world that can’t access it is lowering the dose? A ...

Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning Pharmalittle newsletter ...

Isabella is a chronic disease reporter writing about how the Trump administration is tackling the nation’s health epidemic — or not. You can reach her on Signal at isabellacueto.03. WASHINGTON — ...

Calley Means, a MAHA leader who just resigned from the Trump administration, says Americans "are being duped and gaslighted ...

Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning Pharmalittle newsletter ...

Mario covers technology in health care, including FDA regulation of artificial intelligence; how Medicare pays for health tech; the use of AI in clinical care; mental health chatbots; and consumer ...

President Donald Trump is promising more payments to voters just ahead of the Nov. 3 midterm elections — this time, to more than 20 million seniors, giving them $90 each to help pay for Medicare ...

Lizzy led STAT’s coverage of the FDA. Her stories explore the relationship between politics and science at the FDA, industry influence, and the agency’s ability to protect and promote public health.